CCR7 and myeloid sarcoma: We could previously demonstrate that in fingolimod-treated MS patients CCR7-negative Tcon expand and are more prone to Treg mediated suppression when tested in in vitro proliferation assays, thereby indirectly upregulating Treg efficiency (30).